Literature DB >> 12766839

The impact of antimicrobial resistance on health and economic outcomes.

Sara E Cosgrove1, Yehuda Carmeli.   

Abstract

Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in the administration of appropriate therapy, and limiting available therapy. Next, we examine the different perspectives held by hospitals, third-party payers, patients, and society on the impact of resistance. Finally, we review methodological issues in designing and assessing studies that address the clinical outcomes for patients infected or colonized with resistant pathogens, including adjustment for important confounding variables, control group selection, and the quantification of economic outcomes.

Entities:  

Mesh:

Year:  2003        PMID: 12766839     DOI: 10.1086/375081

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  134 in total

1.  The association between antibiotic use and resistance: the role of secondary antibiotics.

Authors:  J A Bosso; P D Mauldin; C D Salgado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-10       Impact factor: 3.267

2.  Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998.

Authors:  Hilmar Wisplinghoff; Birgitta Ewertz; Susanne Wisplinghoff; Danuta Stefanik; Georg Plum; Francoise Perdreau-Remington; Harald Seifert
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Keith S Kaye; Ronen Ben-Ami; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008-2014.

Authors:  Marta Mascarello; Omar Simonetti; Anna Knezevich; Ludovica Ilaria Carniel; Jacopo Monticelli; Marina Busetti; Paolo Schincariol; Lucio Torelli; Roberto Luzzati
Journal:  Infection       Date:  2017-03-06       Impact factor: 3.553

5.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Antimicrobial stewardship - can we afford to do without it?

Authors:  Anna Aryee; Nicholas Price
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 8.  Critical issues in the clinical management of complicated intra-abdominal infections.

Authors:  Stijn Blot; Jan J De Waele
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort.

Authors:  Anne M Butler; Margaret A Olsen; Liana R Merz; Rebecca M Guth; Keith F Woeltje; Bernard C Camins; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-01       Impact factor: 3.254

10.  Nonthermal Plasma Jet Treatment Negatively Affects the Viability and Structure of Candida albicans SC5314 Biofilms.

Authors:  O Handorf; T Weihe; S Bekeschus; A C Graf; U Schnabel; K Riedel; J Ehlbeck
Journal:  Appl Environ Microbiol       Date:  2018-10-17       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.